Scope & Patent Claims Analysis for U.S. Drug Patent 9,861,631 (Brimonidine Tartrate 0.5% Topical Rosacea Erythema, Once-Daily, Polyol/Gel System, Clinician + Patient 12-Hour “Success Profile”)
U.S. Patent 9,861,631 is directed to a method of treating facial erythema associated with rosacea using a once-daily topical brimonidine tartrate composition with a defined polyol load, a defined gelling agent (carbomer grades), and a performance criterion framed as a “12 hour success profile” with both clinician and patient assessments and an explicit grade-improvement window. Claim scope is defined less by pharmacology and more by formulation architecture plus trial outcome characterization.
What does US Patent 9,861,631 claim coverage for rosacea erythema treatment?
Short answer: It covers once-daily topical treatment of facial erythema in rosacea using 0.5% brimonidine tartrate in a specific polyol + carbomer gel/carrier system, where the regimen produces predefined clinician and patient improvements at 12 hours and includes optional sub-windows for 2-grade improvement.
Core claim 1 elements (independent method claim)
Claim 1’s structure sets a three-part test: (i) regimen and target, (ii) composition constraints, (iii) efficacy + safety outcome constraints.
-
Method / patient / condition
- Treat facial erythema associated with rosacea.
- “In a subject in need thereof.”
- Once daily topical administration to facial skin area affected by erythema.
-
Composition (relative to total weight of composition)
- 0.5% by weight brimonidine tartrate.
- Polyols: “about 8.0% to about 30.0% by weight in total” of one or more polyols.
- Gelling agent: about 0.20% to about 4.0%.
- Pharmaceutically acceptable carrier.
-
Outcome requirement (performance definition)
- Efficacy: “more reduction of the facial erythema compared to a vehicle control”
- Measured by two endpoints:
- Clinician’s Erythema Assessment scores
- Patient’s Self Assessment scales
- Timeframe: a “12 hour success profile”
- Success threshold: “at least a 1-grade improvement”
- Safety constraint: “without causing unacceptable drug related adverse events.”
Practical scope implication: Even if a competitor uses brimonidine tartrate 0.5%, once-daily, they still need to satisfy the formulation bounds and the specific responder profile criteria tied to both clinician and patient measures vs vehicle.
How do the dependent claims narrow the formulation and efficacy window in 9,861,631?
Claim 2: time-bound 2-grade improvement window
Claim 2 depends from claim 1 and adds a specific second-tier efficacy window:
- The 12-hour success profile “further comprises”
- about 1 hour to about 8 hours of a 2-grade improvement of facial erythema.
This creates a timing-specific efficacy sub-criterion. Competitors must match both the existence of 1-grade improvement by 12 hours and the added 2-grade improvement persistence/appearance in the specified time window.
Claim 3: narrower window for 2-grade improvement
Claim 3 depends from claim 1 and specifies an alternative sub-window:
- “about 3 hours to about 6 hours” of a 2-grade improvement.
This is a distinct claim variant. If the underlying evidence supports only one window, design-around via selecting a window outside the defined ranges may still fail, because the claims read as requiring the specified window “further comprises,” which implies the efficacy profile must show that time span.
Claim 4: carbomer-only gelling agent; quantified carbomer range
Claim 4 constrains the gelling agent:
- Gelling agent comprises a carbomer
- Topical composition comprises about 0.5% to about 2.0% carbomer by weight.
This is a major narrowing compared with claim 1’s broad “about 0.20% to about 4.0%” gelling agent range. It also restricts the gel chemistry to carbomer.
Claim 5: specific carbomer grades
Claim 5 further narrows the carbomer identity:
- Carbomer selected from:
- carbomer 934P
- carbomer 974P
- carbomer 980
This creates a more direct formulation-design constraint than general “carbomer” language. If a competitor uses a different carbomer grade (or another gelling polymer entirely), they avoid the literal carbomer-grade limitation, assuming they do not meet the claim via other dependent paths.
Claim 6: two polyols with independent ranges
Claim 6 adds a polyol architecture constraint:
- Topical composition comprises a first polyol and a second polyol
- Each polyol is independently about 4% to about 15% by weight relative to total composition.
Compared with claim 1’s “total polyols” range, claim 6 constrains distribution across individual polyols, not only total content.
What additional coverage does claim 7 expand beyond claim 1?
Claim 7 depends from claim 1 but swaps/relaxes certain composition parameters and restates efficacy with an embedded range set for 2-grade improvement.
Composition differences
- Still: 0.5% brimonidine tartrate
- Polyols: “about 5.0% to about 30.0% by weight of at least one polyol”
- This is broader downward than claim 1 (claim 1 starts at 8.0%).
- Gelling agent:
- about 0.5% to about 2.0% by weight
- and must comprise carbomer selected from 934P / 974P / 980.
Efficacy and timing dual-range requirement
Claim 7 requires:
- 12-hour success profile includes at least a 1-grade improvement
- plus “about 1 hour to about 8 hours OR about 3 hours to about 6 hours” of 2-grade improvement.
This “OR” framing means a formulation that produces either timing profile may satisfy this dependent claim. Claim 2 and claim 3 look more like discrete branches; claim 7 gives alternative windows inside one claim.
Scope effect
Claim 7 increases the chance of literal coverage for competitors who formulate with polyol totals below 8.0% but not below 5.0%, and who use carbomer grades as specified.
What does claim 8 add about preservatives and stability?
Claim 8 depends from claim 7 and adds a preservative limitation:
- Optional additional constraint: composition further comprises a preservative selected from:
- sodium benzoate
- phenoxyethanol
- benzyl alcohol
- methylparaben
- imidazolidinyl urea
- diazolidinyl urea
This does not appear required for the independent coverage in claim 1–7, but if a competitor product includes one of these preservatives and meets all other parameters, claim 8 could strengthen infringement arguments for an accused product matching the full formulation.
How is the “12 hour success profile” constructed, and why does it matter for infringement?
Mechanics of the outcome limitation
The claims require treatment to result in:
- “more reduction” vs vehicle control
- assessed using both:
- Clinician’s Erythema Assessment scores
- Patient’s Self Assessment scales
- within the 12 hour success profile definition
- success includes at least 1-grade improvement
- safety includes “without causing unacceptable drug related adverse events”
Infringement leverage
Outcome-based limitations create two litigation-relevant pressure points:
-
Efficacy evidence
- The accused product’s clinical performance must map to the claim’s responder-grade/time windows.
- For generic entry, the usual bioequivalence framework does not directly address a topical gel’s clinical grader endpoints, so litigation will likely hinge on clinical study comparability or bridging evidence.
-
Formulation-to-response link
- Because the claims also tie composition parameters (polyols, carbomer type/level), a defendant can argue non-infringement by showing a different gel system or polyol scheme that changes the pharmacodynamic time course, potentially failing the 2-grade window and/or clinician-patient dual criteria.
What formulation “design-around” options exist relative to the claim language?
Because the claims include multiple “hard” constraints, design-arounds typically target one of the following levers.
1) Avoid 0.5% brimonidine tartrate
If the active concentration is not 0.5% by weight, the literal claims 1 and 7 are not met. That is the cleanest design-around, though it may shift regulatory and performance requirements.
2) Change polyol content or polyol distribution
- Claim 1 requires 8.0% to 30.0% total polyols.
- Claim 7 allows 5.0% to 30.0%.
- Claim 6 constrains the case of two polyols, requiring each in 4% to 15%.
Using a polyol system outside these ranges can defeat literal scope. But any shift in polyol composition must still preserve clinical outcomes to avoid “success profile” inference, and must support skin tolerability.
3) Replace carbomer with another gelling agent or carbomer grade
- Claim 4 restricts gelling agent to carbomer, and claim 5 lists specific grades.
- If a competitor uses a different carbomer grade not listed (or a non-carbomer gelling polymer), it may avoid dependent claim 5 and also avoid the “gelling agent comprises carbomer selected from…” constraint of claim 7.
However, claim 1’s gelling agent is not limited to carbomer by identity, only by quantity (“about 0.20% to about 4.0%”). So to fully escape, a defendant likely needs to alter either the gelling agent identity along with the polyol bounds (or other elements) so that the composition no longer falls within claim 1’s literal terms.
4) Miss the 2-grade improvement time window
Claim 2 requires 2-grade improvement from 1–8 hours, and claim 3 requires 3–6 hours. Claim 7 includes either window.
A defendant might try to position product response outside these windows. But “OR” in claim 7 reduces straightforward avoidance: if clinical response hits either window, claim 7 can still read on the profile.
5) Fail the dual endpoint requirement
Claims require both clinician and patient improvements evaluated on the 12-hour success profile. If an accused product produces clinician improvement but not patient self-assessment, or vice versa, literal infringement becomes less direct. In practice, clinical study endpoints for rosacea erythema are often correlated, so this can be harder than it sounds, but the requirement is explicit.
Patent landscape context: what 9,861,631 is likely positioned against in the US market?
What the claims signal about the broader estate
The claim set is tightly aligned with a branded, topical rosacea erythema product platform that uses brimonidine tartrate 0.5% and a gel vehicle with polyols and carbomer. In US patent portfolios for dermatology actives, it is typical that:
- independent method claims like this are paired with:
- formulation composition claims,
- dependent claims covering specific carbomer grades and polyol classes,
- clinical endpoint-defined claims (clinician + patient, time-to-response windows),
- and sometimes kit or manufacturing method claims.
Business relevance
For R&D and licensing, the key question is not “is brimonidine tartrate known,” but whether the competitor’s product is engineered to satisfy or avoid:
- the polyol content bounds,
- carbomer type/level,
- and the explicit 12-hour success profile and 2-grade timing behavior.
How strong is the claim set relative to typical US topical generic challenges (Paragraph IV / design-around)?
Why the claims can be difficult to avoid
- Multiple constraints stack: concentration + polyols + gelling agent quantity + carbomer identity + carbomer grades + time-bound dual-parameter endpoints.
- For generic-like formulations, product sameness is often targeted to meet performance, which increases the chance of matching the same clinical response profile.
Where defendants may attack
- Formulation divergence (polyol totals/distribution; gelling agent type/grade).
- Clinical profile divergence (2-grade timing; “success profile” threshold; clinician vs patient endpoint alignment).
- Safety/tolerability (“unacceptable drug related adverse events” can be argued based on study data and regulatory outcomes).
What does the claim language imply for FDA regulatory status and Orange Book risk?
The claims read like a typical US-listed patent intended to be tied to an FDA-approved topical drug for rosacea erythema. For an Orange Book strategy, the relevant risk is that the patent is positioned to cover the commercial dosage form and labeled dosing concept: once daily topical brimonidine tartrate 0.5% with a vehicle designed to deliver a response profile by 12 hours.
This is exactly the profile shape that tends to be used in US Orange Book listing narratives and in later infringement assertions: endpoint-defined methods tied to formulation and dosing.
Key takeaways
- U.S. Patent 9,861,631 is a once-daily topical rosacea facial erythema method patent tied to 0.5% brimonidine tartrate and a polyol + carbomer gel system with defined quantitative bounds.
- Claim scope is gated by an explicit “12 hour success profile” using both clinician and patient assessments, requiring at least a 1-grade improvement versus vehicle, with an adverse-event safety qualifier.
- Dependent claims hard-code 2-grade improvement timing windows (1–8 hours or 3–6 hours) and restrict the gelling agent to carbomer with enumerated grades (934P/974P/980).
- Potential design-arounds concentrate on: changing brimonidine concentration, moving polyol totals outside claim ranges, substituting gelling agents or carbomer grades, or engineering clinical response to avoid the defined 2-grade time windows and/or dual endpoint success.
FAQs
1) Does U.S. Patent 9,861,631 cover any brimonidine tartrate topical product for rosacea, or only 0.5%?
The independent method claim requires 0.5% by weight brimonidine tartrate in the topical composition.
2) Is “carbomer” required for infringement of claim 1?
Claim 1 requires a gelling agent in a quantity range but does not restrict the gelling agent’s identity to carbomer; carbomer-specific constraints appear in dependent claims.
3) What happens if a product achieves 1-grade improvement at 12 hours but not 2-grade improvement in the specified window?
Claim 2/3/7 depend on additional 2-grade timing elements. Missing those windows can avoid those dependent claims, though claim 1 still requires the 12-hour 1-grade success profile.
4) Can a product avoid claim coverage by excluding preservatives listed in claim 8?
Yes for claim 8’s specific limitation, but claims 1–7 do not require those preservatives.
5) How do the clinician and patient endpoints affect litigation strategy for a topical generic?
The success profile is defined by both clinician erythema assessment and patient self-assessment, so infringement arguments can hinge on whether both endpoints meet the grade/time thresholds versus vehicle.
References (APA)
- U.S. Patent 9,861,631.
